These encouraging results as a monotherapy promoted the development of a phase Ib/II clinical trial to determine the safety, tolerability, and antileukemic activity in combination with azacitidine and/or venetoclax in patients with relapsed and CD123+ AML (NCT04086264). The gene discussed is IL3RA; the disease is acute myeloid leukemia.